Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392469 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT01392469 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT01392469, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
Interventions
- DRUG Bosentan
- DRUG Imatinib
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-04-20 |
| Est. Completion | 2012-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01392469
The ClinicalTrials.gov registry entry for NCT01392469 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bosentan is the first listed.
NCT01392469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01392469 about?
NCT01392469 is a clinical study titled "Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants". The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
What is the current status of trial NCT01392469?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2011-04-20. Estimated completion is 2012-10-25.
What interventions are being tested in trial NCT01392469?
The interventions under investigation include: Bosentan (DRUG), Imatinib (DRUG), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01392469?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.